国家科技部中国科技论文统计源期刊   中国科技核心期刊   WHO西太平洋地区医学索引(WPRIM)收录期刊   湖北优秀期刊
《药物流行病学杂志》官方网站与投审稿系统变更通知<点击查看详情>
吉西他滨联合顺铂用于非小细胞肺癌术后化疗疗效观察
Efficacy and Safety of Gemcitabine Combined with Cisplatin on Postoperative Adjuvant Chemotherapy in Non small Cell Lung Cancer
  
DOI:
中文关键词:  辅助化疗  非小细胞肺癌  吉西他滨  顺铂  复发率
英文关键词:Adjuvant chemotherapy  Non small cell lung cancer  Gemcitabine  Cisplatin  Recurrence rate
基金项目:浙江省医药卫生一般研究计划(B类)(编号:2013KYB300)
作者单位
潘建虹 丽水市人民医院胸心外科(浙江丽水 323000) 
何玮 丽水市人民医院胸心外科 
彭丛兄 丽水市人民医院胸心外科 
摘要点击次数: 3700
全文下载次数: 4366
中文摘要:
      摘 要 目的:观察吉西他滨联合顺铂对非小细胞肺癌(NSCLC)术后化疗的疗效及安全性。方法:116例经手术治疗的NSCLC患者随机分为观察组和对照组,分别在术后给予GP化疗方案(吉西他滨+顺铂)和NP化疗方案(长春瑞滨+顺铂),21 d为1周期,化疗4个周期。比较两组近期疗效、药品不良反应和1年复发率。结果:观察组总缓解率为48.28% (28/58),对照组总缓解率为46.55% (27/58),两组比较,差异无统计学意义(P>0.05)。两组Ⅲ+Ⅳ级的胃肠道反应、贫血、白细胞减少、粒细胞减少和血小板减少发生率比较,差异均无统计学意义(P>0.05)。 观察组和对照组1年复发率分别为10.34% (6/58)和13.79% (8/58),差异无统计学意义(P>0.05)。结论:吉西他滨联合顺铂辅助NSCLC术后化疗的疗效、药品不良反应及1年复发率均与NP方案相当。
英文摘要:
      ABSTRACT Objective: To investigate the efficacy and safety of postoperative adjuvant chemotherapy with gemcita bine combined with cisplatin in the treatment of non small cell lung cancer(NSCLC). Methods:116 cases patients with NSCLC ungerwent surgery were randomly divided into observation group and control group. GP(gemcitabine+cisplatin) or NP(vinorelbine+cisplatin) chemotherapy regimen were treated respectively for 4 cycles with each for 21 days. The recent curative effect, adverse reactions and one year recurrence rate were compared between the two groups. Results: The overall response rate was 48.28% (28/58) in observation group, campared to 46.55% (27/58) in control group, there had no statistical significance (P>0.05). Compared the incidences of Ⅲ + Ⅳ levels of gastrointestinal reaction, anemia, leukopenia, granulocytopenia and thrombocytopenia between the two groups, there had no statistical significance(P>0.05). The one year recurrence rate was 10.34% (6/58) in observation group and 13.79%(8/58) in control group, which had no statistical significance (P>0.05).Conclusion:Gemcitabine combined with cisplatin on postoperative adjuvant chemotherapy in NSCLC had distinct curative effect, tolerance of adverse reaction and low long term recurrence rate, which were all similar to NP chemotherapy regimen.
查看全文  查看/发表评论  下载PDF阅读器
关闭